Chemiluminescence Immunoassay Analyzer Market Report 2026

Chemiluminescence Immunoassay Analyzer Market Overview

• Chemiluminescence Immunoassay Analyzer market size has reached to $6.03 billion in 2025 • Expected to grow to $8.15 billion in 2030 at a compound annual growth rate (CAGR) of 6% • Growth Driver: Rising Chronic Diseases Fuels Chemiluminescence Immunoassay Analyzer Market Growth • Market Trend: Innovative Developments In Chemiluminescence Immunoassay Analyzers Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Chemiluminescence Immunoassay Analyzer Market?

Chemiluminescence immunoassay (CLIA) analyzers are sophisticated laboratory instruments used to detect and measure various substances, such as proteins, hormones, and drugs, within a sample by employing the principles of chemiluminescence and immunoassay techniques. It is widely used in clinical laboratories for high-sensitivity detection of hormones, proteins, antibodies, and infectious agents due to its precise and automated detection capabilities. The main types of chemiluminescence immunoassay analyzers are fully automated chemiluminescence immunoassay analyzers and semi-automated chemiluminescence immunoassay analyzers. Fully automated chemiluminescence immunoassay analyzers are advanced laboratory devices that utilize chemiluminescence to automatically measure and analyze the presence of specific proteins, hormones, and other molecules in biological samples with high sensitivity and accuracy. It has several technologies, such as sequential injection, random access, and batch analyzers, and it is applied for oncology and endocrinology, hepatitis and retroviruses, cardiac markers, infectious disease, bone and mineral disorders, auto-immune diseases, allergies, gastrointestinal (GI) stool testing, and drug discovery and development. It is used by various end users, including hospitals and clinics, medical and diagnostic laboratories, and pharmaceutical companies.

What Is The Chemiluminescence Immunoassay Analyzer Market Growth Forecast?

The chemiluminescence immunoassay analyzer market size is expected to see strong growth in the next few years. It will grow to $8.15 billion in 2030 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to rising burden of chronic and autoimmune diseases, increasing demand for early disease detection, expansion of diagnostic testing in emerging markets, growing focus on laboratory workflow efficiency, rising adoption of point-of-care immunoassay solutions. Major trends in the forecast period include rising demand for high-sensitivity diagnostic testing, increasing adoption of fully automated immunoassay systems, growing use of CLIA analyzers in infectious disease testing, expansion of CLIA applications in oncology and endocrinology, increasing preference for high-throughput laboratory analyzers.

Global Chemiluminescence Immunoassay Analyzer Market Segmentation

1) By Product: Fully Automated Chemiluminescence Immunoassay Analyzers, Semi-Automated Chemiluminescence Immunoassay Analyzers 2) By Technology: Sequential Injection, Random Access, Batch Analyzers 3) By Application: Oncology And Endocrinology, Hepatitis And Retroviruses, Cardiac Markers, Infectious Disease, Bone And Mineral Disorders, Auto-Immune Diseases, Allergy, Gastrointestinal (GI) Stool Testing, Drug Discovery And Development 4) By End User: Hospitals And Clinics, Medical And Diagnostic Laboratories, Pharmaceutical Companies Subsegments: 1) By Fully Automated Chemiluminescence Immunoassay Analyzers: High-Throughput Analyzers, Medium-Throughput Analyzers, Low-Throughput Analyzers 2) By Semi-Automated Chemiluminescence Immunoassay Analyzers: Bench-Top Analyzers, Portable Or Point-Of-Care Analyzers

What Is The Driver Of The Chemiluminescence Immunoassay Analyzer Market?

The rising prevalence of chronic diseases is expected to propel the growth of the chemiluminescence immunoassay analyzer market going forward. Chronic diseases are on the rise due to factors such as aging populations, unhealthy lifestyles, and improvements in medical care that allow people with acute conditions to survive longer, thus increasing the prevalence of long-term health issues. Chemiluminescence immunoassay analyzers are utilized in chronic disease management for precise and sensitive detection of biomarkers, aiding in accurate diagnosis and treatment monitoring. For instance, in April 2025, according to the Centers for Disease Control and Prevention (CDC), a US-based federal agency, in 2023, approximately 194 million U.S. adults, or 76.4%, reported having at least one chronic condition. The prevalence was 59.5% among young adults, 78.4% among midlife adults, and 93.0% among older adults. Therefore, the rising prevalence of chronic diseases is driving the growth of the chemiluminescence immunoassay analyzer industry.

Key Players In The Global Chemiluminescence Immunoassay Analyzer Market

Major companies operating in the chemiluminescence immunoassay analyzer market are F. Hoffmann-La Roche AG, Abbott Laboratories Inc., Siemens Healthineers AG, Wiener Lab Group, PerkinElmer Inc., BioMérieux SA, Beckman Coulter Life Sciences, Tosoh Bioscience LLC, Bio-Rad Laboratories Inc., Shenzhen Mindray Bio-Medical Electronics Co. Ltd., DiaSorin SpA, Euroimmun AG, Autobio Diagnostics Co. Ltd., Maccura Biotechnology Co. Ltd., Luminex Corporation, Fujirebio Holdings Inc., Randox Laboratories Ltd., Shenzhen Yhlo Biotech Co. Ltd., Addcare Bio-Tech Co. Ltd., Inova Diagnostics, Immunodiagnostic Systems Holdings (IDS), Dynex Technologies Inc., Nanjing Poclight Biotechnology Co. Ltd.

Global Chemiluminescence Immunoassay Analyzer Market Trends and Insights

Major companies operating in the chemiluminescence immunoassay analyzer market are developing advanced diagnostic technologies, such as automated analyzers, to help in decision-making or further analysis. An automated analyzer is a device or system that performs analytical processes automatically and is typically used in medical laboratories for efficient and accurate testing of samples. For instance, in July 2023, Fapon Biotech Inc., a China-based life sciences company, launched the Shine i8000/9000 chemiluminescence immunoassay system. The high-speed, fully automated analyzer operates at an ultra-high throughput of 900 tests per hour, empowering its partners to develop top-tier clinical diagnostic solutions. The system provides initial findings in only 10 minutes, offering swift insights crucial for time-sensitive situations. It operates at a rapid testing pace of 900 tests per hour and has a high throughput capacity of 377 tests per hour per square meter, efficiently managing large sample volumes while maintaining reliable accuracy. This makes it particularly suitable for medium- to large-scale laboratories.

What Are Latest Mergers And Acquisitions In The Chemiluminescence Immunoassay Analyzer Market?

In November 2023, LASCCO, a Switzerland-based biotechnology company and Abionic SA, Switzerland-based biotechnology company signed a licensing agreement with Fapon, granting Fapon the rights to develop and commercialize the PSP (point-of-sample testing) technology. Under this agreement, Fapon will integrate the PSP technology into its chemiluminescent immunoassay (CLIA) analyzer, targeting the Chinese market. Fapon Biotech is a China-based provider of total solutions in the in vitro diagnostics (IVD) industry.

Regional Outlook

North America was the largest region in the chemiluminescence immunoassay analyzers market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Chemiluminescence Immunoassay Analyzer Market?

The chemiluminescence immunoassay analyzer market consists of sales of pacifier thermometers, automated instrumentation, quality control materials, and related products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.